Identification of mechanisms underlying the attenuation of viruses by codon pair deoptimization
Identification of mechanisms underlying the attenuation of viruses by codon pair deoptimization
批准号:
424925074
负责人:
Privatdozent Dr. Michael Veit, since 7/2020
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2019
资助国家:
德国
项目状态:
已结题
起止时间:
2018-12-31 至 2022-12-31
中文摘要
使用传统方法开发疫苗耗时、费力且不可预测,并且在最需要对新出现的传染病做出反应时失败。密码子对去最优化减毒(CPD)是一种新的策略,能够高效和快速地减毒多种病毒,包括脊髓灰质炎病毒和登革热病毒。CPD的衰减是基于对病毒基因组的大规模重新编码。它涉及病毒基因中密码子的重新洗牌,而不改变密码子偏向或编码蛋白质的氨基酸组成。重组的目标是最大限度地增加宿主基因组中代表不足的密码子对的数量,因为密码子对去优化的病毒复制效率比它们的野生型亲本低得多。CPD具有巨大的潜力,因为它适用于许多动物或人类病毒和其他病原体的减毒。然而,CPD方法的主要缺点是导致衰减的分子机制仍然难以捉摸。CPD在重新编码的基因中引入了数百个核苷酸突变,但尚不清楚哪些引入的基因变化是导致衰减的原因。在这个问题得到解决之前,将不可能在临床环境中使用重新编码的病毒疫苗。此外,也不可能通过监测减毒病毒的基因变化来检查衰减的逆转。一旦我们了解了CPD减毒的分子基础,就有可能改进减毒设计并生产更好、更安全的病毒疫苗。该项目的主要目标是确定CPD衰减的确切分子机制。为了达到这个项目的目标,我们将使用H1N1流感病毒作为模型病毒,H1N1流感病毒是人类的重要病原体。我们已经准备了一系列重新编码的H1N1突变体,在这些突变体中,我们独立地改变了两个可能导致衰减的主要序列特征--未被充分代表的密码子对的数量和类型,以及CpG二核苷酸的数量。我们的初步研究是这一提议的关键,因为他们明确地证实,在体外,将未被充分代表的密码子对而不是CpG二核苷酸引入到重新编码的基因中会导致重新编码的病毒的衰减。在这个项目中,我们将解决CPD衰减的四个主要未知数。我们将:i)准确地确定哪些密码子对是重编病毒减毒的主要原因;ii)确定代表性不足的密码子对如何扰乱导致H1N1病毒减毒的分子机制;iii)量化减毒病毒在体外广泛传代后恢复毒力的能力;iv)比较密码子去优化、密码子去优化或CpG最大化的病毒的减毒水平和疫苗效力,并确定三种重编码方法中哪种在体内对H1N1病毒的减毒效果更好。
英文摘要
Vaccine development using traditional approaches is time-consuming, laborious and unpredictable and fails when response to newly emerging infectious diseases is needed the most. Attenuation by codon pair deoptimization (CPD) is a new strategy that has enabled highly efficient and rapid attenuation of a wide variety of viruses, including poliovirus and Dengue virus. The attenuation by CPD is based on large-scale recoding of viral genomes. It involves reshuffling of codons in viral genes without changing the codon bias or amino acid composition of the encoded proteins. The goal of reshuffling is to maximize the number of codon pairs that are underrepresented in the host genome, because codon pair deoptimized viruses replicate much less efficiently as their wild type parents. CPD has an immense potential, because it is applicable for attenuation of many animal or human viruses and other pathogens. The major drawback of the CPD approach is, however, that the molecular mechanisms that result in attenuation have remained elusive. CPD introduces several hundred nucleotide mutations into recoded genes, but it is not known which of the introduced genetic changes are responsible for attenuation. Until this problem is solved it will not be possible to utilize recoded viral vaccines in the clinical settings. Also, it will not be possible examine the reversion of attenuation through monitoring of genetic changes in attenuated viruses. Once we understand the molecular basis of attenuation by CPD it will be possible to refine the attenuation design and produce better and safer viral vaccines. The main goal of this project is to identify the exact molecular mechanisms that underlie the attenuation by CPD. To attain the objective of this project we will use H1N1 influenza virus, an important human pathogen, as a model virus. We have prepared a series of recoded H1N1 mutants in which we independently varied two main sequence features that are suspected to underlie the attenuation – the number and type of underrepresented codon pairs, and the number of CpG dinucleotides. Our preliminary studies are key for this proposal, because they unequivocally confirmed that introduction of underrepresented codon pairs, but not CpG dinucleotides into recoded genes leads to attenuation of recoded viruses in vitro. During this project we will solve four major unknowns of the attenuation by CPD. We will i) identify exactly which codon pairs are principally responsible for attenuation of recoded viruses; ii) establish how underrepresented codon pairs perturb molecular mechanisms that lead to attenuation; iii) quantify the capacity of attenuated viruses to revert to virulence upon extensive passage in vitro; iv) compare the level of attenuation and vaccine efficacy of codon-deoptimized, codon pair-deoptimized, or CpG-maximized viruses and determine which of the three recoding methods is superior for attenuation of H1N1 virus in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
Exploring the Intrinsic Mechanisms of CEO Turnover and Market
-
批准号:--
-
项目类别:外国学者研究基金
-
资助金额:--
-
批准年份:2024
-
负责人:HAOFEI Z
-
依托单位:
Exploring the Intrinsic Mechanisms of CEO Turnover and Market Reaction: An Explanation Based on Information Asymmetry
-
批准号:W2433169
-
项目类别:外国学者研究基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:HAOFEI ZHANG
-
依托单位:
Erk1/2/CREB/BDNF通路在CSF1R相关性白质脑病致病机制中的作用研究
-
批准号:82371255
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:曹立
-
依托单位:
Foxc2介导Syap1/Akt信号通路调控破骨/成骨细胞分化促进颞下颌关节骨关节炎的机制研究
-
批准号:82370979
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张善勇
-
依托单位:
MYRF/SLC7A11调控施万细胞铁死亡在三叉神经痛脱髓鞘病变中的作用和分子机制研究
-
批准号:82370981
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:陈敏洁
-
依托单位:
Idh3a作为线粒体代谢—表观遗传检查点调控产热脂肪功能的机制研究
-
批准号:82370851
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:包玉倩
-
依托单位:
小脑浦肯野细胞突触异常在特发性震颤中的作用机制及靶向干预研究
-
批准号:82371248
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:吴逸雯
-
依托单位:
用于小尺寸管道高分辨成像荧光聚合物点的构建、成像机制及应用研究
-
批准号:82372015
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:熊丽琴
-
依托单位:
声致离子电流促进小胶质细胞M2极化阻断再生神经瘢痕退变免疫机制
-
批准号:82371973
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:孙迪
-
依托单位:
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
-
批准号:82371652
-
项目类别:面上项目
-
资助金额:45.00万元
-
批准年份:2023
-
负责人:刘开江
-
依托单位: